Scope
NICE guideline NG97 covers dementia across the care pathway. It addresses initial assessment and referral, specialist subtype diagnosis and further testing, and distinguishing delirium from dementia. It also covers information, advance care planning, care coordination, and non-drug and drug interventions for cognition. Further topics are distress, mood, sleep and pain; palliative care and nutrition; and support for carers. Several Alzheimer's disease drug recommendations come from a NICE technology appraisal.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Initial assessment, referral and delirium
- Take a history of cognitive, behavioural and psychological symptoms and their effect on daily life. Take it from the person with suspected dementia and, if possible, from someone who knows them well. Consider supplementing the informant history with IQCODE or FAQ. If dementia is still suspected, examine the person and do appropriate blood and urine tests to exclude reversible causes. Then use a validated brief structured cognitive instrument. A normal score alone does not rule out dementia. [1]
- Refer to a specialist dementia diagnostic service, such as a memory clinic, when two conditions are met. First, reversible causes have been investigated, including delirium, depression, sensory impairment and medicines with anticholinergic burden. Second, dementia is still suspected. Refer suspected rapidly progressive dementia to a neurological service with access to tests for Creutzfeldt–Jakob disease, including cerebrospinal fluid examination. [1]
- Case finding for suspected dementia should only be done within a clinical trial that also provides an intervention for people diagnosed. [1]
- For hospital patients with cognitive impairment of unknown cause, consider the long CAM or OSLA to identify delirium, with or without dementia. Do not use standardised instruments alone to make this distinction. If the cause remains unclear, treat for delirium first. [1]
Specialist subtype diagnosis and further tests
- Diagnose a subtype where possible once specialist assessment confirms decline and reversible causes are excluded. Include verbal episodic memory testing if Alzheimer's is suspected, and use validated subtype criteria. Offer structural imaging unless dementia is well established and the subtype is clear. Consider further tests only if they would help diagnose the subtype and the result would change management. [1]
- If the diagnosis is uncertain and Alzheimer's is suspected, consider one of two options. The first is FDG-PET, or perfusion SPECT if FDG-PET is unavailable. The second is CSF testing for tau (total tau, or total tau and phosphorylated-tau 181) and amyloid (amyloid beta 1–42, or amyloid beta 1–42 and 1–40). If the first test is non-diagnostic, consider the other. CSF false positives become more likely with age. Do not exclude Alzheimer's on CT or MRI alone, and do not use APOE genotyping or EEG to diagnose it. [1]
- If the diagnosis is uncertain and dementia with Lewy bodies is suspected, use FP-CIT SPECT. If it is unavailable, consider MIBG cardiac scintigraphy. Normal results on either test do not rule out the diagnosis. [1]
- If the diagnosis is uncertain and frontotemporal dementia is suspected, use FDG-PET or perfusion SPECT; no imaging result alone rules it out. For suspected vascular dementia with an uncertain subtype, use MRI, or CT if MRI is unavailable or contraindicated. Do not diagnose vascular dementia on vascular lesion burden alone. [1]
Information, advance planning and coordination
- At diagnosis, offer oral and written information on the following topics: - the subtype and how it is expected to progress - the professionals involved and how to contact them - driving where appropriate, including the need to tell the DVLA and their insurer - legal rights - workplace reasonable adjustments - how to contact support groups and charities [1]
- Offer early and ongoing discussions about planning ahead, lasting power of attorney, advance statements and advance decisions to refuse treatment. Include preferred place of care and place of death. Offer the chance to review these at each care review. [1]
- Provide a single named coordinating professional. They should arrange a needs assessment, face to face if possible. They should also develop a care and support plan that states when it will be reviewed and covers comorbidities. After diagnosis, ensure access to a memory service or equivalent multidisciplinary dementia service. [1]
Non-drug interventions for cognition and wellbeing
- Offer wellbeing activities tailored to the person's preferences. In mild to moderate dementia, offer group cognitive stimulation therapy. Also consider group reminiscence therapy, and cognitive rehabilitation or occupational therapy to support functional ability. [1]
- Do not offer acupuncture, ginseng, vitamin E supplements or herbal formulations to treat dementia. For mild to moderate Alzheimer's disease, do not offer cognitive training, or interpersonal therapy for cognitive symptoms. Do not offer non-invasive brain stimulation, including transcranial magnetic stimulation, to treat mild to moderate Alzheimer's disease, except as part of a randomised controlled trial. [1]
Pharmacological management
- Donepezil, galantamine and rivastigmine monotherapy are options for mild to moderate Alzheimer's disease. Memantine monotherapy is an option in moderate disease with AChE inhibitor intolerance or contraindication, or in severe disease. For people with established Alzheimer's already taking an AChE inhibitor, consider adding memantine in moderate disease and offer it in severe disease. [1]
- For people not already taking these drugs, start an AChE inhibitor or memantine only on the advice of a clinician with the necessary knowledge and skills. This can include GPs, nurse consultants and advanced nurse practitioners with specialist expertise in diagnosing and treating Alzheimer's disease. The first prescription may then be issued in primary care. For people with an established Alzheimer's diagnosis already taking an AChE inhibitor, primary care may add memantine without specialist advice. Normally start with the lowest-cost AChE inhibitor, unless an alternative is more appropriate. Do not stop AChE inhibitors because of disease severity alone. [1]
- When judging Alzheimer's severity and treatment need, do not rely solely on cognition scores where disabilities, communication or language difficulties, or education level make them inappropriate. Use another suitable method to decide on starting or continuing treatment. [1]
- In mild to moderate dementia with Lewy bodies, offer donepezil or rivastigmine. Consider galantamine only if neither is tolerated. In severe dementia with Lewy bodies, consider donepezil or rivastigmine. Separately, consider memantine for people with dementia with Lewy bodies if AChE inhibitors are not tolerated or are contraindicated. These uses were off label as of June 2018. [1]
- In vascular dementia, consider AChE inhibitors or memantine only with suspected comorbid Alzheimer's disease, Parkinson's disease dementia or dementia with Lewy bodies; this use was off label as of June 2018. Do not offer these drugs for frontotemporal dementia, noting that logopenic aphasia, previously included in some frontotemporal dementia diagnostic guidelines, has now been shown to be most commonly caused by Alzheimer's disease. Do not offer them for cognitive impairment caused by multiple sclerosis. [1]
- Except in randomised controlled trials, do not offer diabetes medicines, hypertension medicines, statins or NSAIDs (including aspirin) specifically to slow Alzheimer's progression. Separately, consider minimising medicines with anticholinergic burden and seeking alternatives where possible. Do this when assessing whether to refer for diagnosis and during medication reviews. [1]
Distress, mood, sleep and pain
- Before treating distress, carry out a structured assessment and address clinical or environmental causes such as pain or delirium. Offer psychosocial and environmental interventions as initial and ongoing management. Offer antipsychotics only for risk of harm to self or others, or for agitation, hallucinations or delusions causing severe distress. Do not offer valproate for agitation or aggression unless it is indicated for another condition. [1]
- Before starting an antipsychotic, discuss benefits and harms, considering a decision aid, and follow the 2012 MHRA advice. Use is off label for almost all antipsychotics. Use the lowest effective dose for the shortest possible time, and reassess at least every 6 weeks. Stop treatment if there is no clear ongoing benefit, after discussion with the person and their carers. In dementia with Lewy bodies or Parkinson's disease dementia, antipsychotics can worsen motor features or cause severe sensitivity reactions. [1]
- In mild to moderate dementia with mild to moderate depression and/or anxiety, consider psychological treatments. Do not routinely offer antidepressants for mild to moderate depression unless indicated for a pre-existing severe mental health problem. Do not offer melatonin for insomnia in Alzheimer's disease. For sleep problems, consider personalised multicomponent sleep management including sleep hygiene education, daylight, exercise and activities. [1]
- Consider a structured observational pain tool in two situations. In moderate to severe dementia, use it alongside self-report and clinical assessment. When self-report is not possible, use it alongside clinical assessment. Consider a stepwise protocol that balances pain management against adverse events. Repeat pain assessment when pain or pain-related behavioural change is apparent, and after any intervention. [1]
Palliative care, nutrition and carers
- Offer flexible, needs-based palliative care from diagnosis. Near the end of life, use anticipatory healthcare planning, applying best-interest decision-making principles if the person lacks capacity. Support eating and drinking, and consider speech and language therapy if there are safety concerns. Do not routinely use enteral feeding in severe dementia unless it is indicated for a potentially reversible comorbidity. [1]
- Offer carers psychoeducation and skills training. This should cover responding to behaviour change, adapting communication and looking after their own health. Ensure support is available from diagnosis and as needed afterwards; group sessions are likely to be most effective. Advise carers of their right to carer and respite assessments, and be aware they are at increased risk of depression. [1]
Limitations and use
- Research recommendations and the nonclinical rationale and update sections were not reviewed. Tables and figures may need the original pages for interpretation.
- Several topics are deferred to other NICE guidelines and not covered here. These include drug management of Parkinson's disease dementia, assessment in people with learning disabilities, delirium treatment, falls, diabetes targets, incontinence, hearing assessment and transitions between care settings.
- Off-label status notes for the non-Alzheimer's dementia drugs and for antipsychotics are dated June 2018. Some Alzheimer's disease drug recommendations are reproduced from a NICE technology appraisal.
- Some recommendations are left out of this summary for brevity. These include hospital admission risk assessment, staff training, service accessibility, eye testing and consent for information sharing.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Dementia: assessment, management and support for people living with dementia and their carers
Guideline recommendation text consulted
Publication details
- Issuing organisation
- NICE
- First published
- 20 June 2018
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.